var data={"title":"Candidal intertrigo","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Candidal intertrigo</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/contributors\" class=\"contributor contributor_credentials\">Eva R Parker, MD, FAAD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/contributors\" class=\"contributor contributor_credentials\">Robert P Dellavalle, MD, PhD, MSPH</a></dd><dd><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/contributors\" class=\"contributor contributor_credentials\">Ted Rosen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/contributors\" class=\"contributor contributor_credentials\">Abena O Ofori, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jul 14, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Intertrigo is any infectious or noninfectious inflammatory condition of two closely opposed skin surfaces (intertriginous area). While it may result from the overgrowth of microorganisms including bacteria, the term often refers to a process that is due to a superficial infection with <em>Candida</em> species. Candidal intertrigo is the most common cutaneous candidal infection of hair-bearing skin (<a href=\"image.htm?imageKey=DERM%2F72073%7EPC%2F78179%7EDERM%2F71145%7EPC%2F79187%7EPEDS%2F62523\" class=\"graphic graphic_picture graphicRef72073 graphicRef78179 graphicRef71145 graphicRef79187 graphicRef62523 \">picture 1A-E</a>) [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/1\" class=\"abstract_t\">1</a>].</p><p>The diagnosis and treatment of candidal intertrigo will be reviewed here. Tinea cruris due to dermatophyte infection is discussed separately. (See <a href=\"topic.htm?path=dermatophyte-tinea-infections\" class=\"medical medical_review\">&quot;Dermatophyte (tinea) infections&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">ETIOLOGY AND RISK FACTORS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The warm, moist environment of the skin folds is ideal for the growth of <em>Candida</em> [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/2\" class=\"abstract_t\">2</a>]. The risk of infection is increased by specific factors that increase skin friction, increase moisture within folds, interfere with the immune response, or promote fungal overgrowth [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/1-7\" class=\"abstract_t\">1-7</a>].</p><p>Factors that may increase skin friction include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Obesity</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clothing (especially tight-fitting clothing) that chafes skin</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Activities that promote skin-on-skin rubbing</p><p/><p>Factors that increase moisture include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Obesity</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Occlusive clothing</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hyperhidrosis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Incontinence</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Occupational exposure to moisture, such as wearing rubber gloves</p><p/><p>Factors that interfere with the immune response or promote fungal overgrowth include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diabetes mellitus</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Use of topical and systemic glucocorticoids</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Use of antibiotics, particularly when chronically or repeatedly administered</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Human immunodeficiency virus (HIV) infection</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chemotherapy</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Immunosuppressant medications</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Occupational exposure to sugar (eg, bakers)</p><p/><p>Recalcitrant candidal intertrigo without an obvious explanation should raise the possibility of underlying or undiagnosed endocrinopathy, malnutrition, malignancy, or HIV infection [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/2\" class=\"abstract_t\">2</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">MICROBIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Candida</em> is a unicellular, dimorphic fungus that produces 3 to 7 micrometer budding yeast cells (blastophores) and 3 to 5 micrometer septate hyphae and pseudohyphae (elongated, filamentous cells connected end to end) in tissue or fluid exudates [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/1,8\" class=\"abstract_t\">1,8</a>]. In cultures incubated at 20&ordm;C, pseudohyphae and chlamydospores are formed. Cultures incubated at 37&ordm;C demonstrate germ tube formation [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/4\" class=\"abstract_t\">4</a>].</p><p>Although there are more than 100 species of <em>Candida</em>, <em>Candida albicans</em> is the most frequent pathogen isolated from candidal intertrigo. Other pathogenic species include <em>Candida tropicalis</em>, <em>Candida krusei</em>, <em>Candida glabrata</em>, <em>Candida parapsilosis</em>, <em>Candida lusitania</em>e, <em>Candida guilliermondii</em>, <em>Candida kefyr</em> (<em>pseudotropicalis</em>), and <em>Candida stellatoidea</em> [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/8,9\" class=\"abstract_t\">8,9</a>].</p><p><em>C. albicans</em> is a commensal organism considered to be normal flora of the gastrointestinal tract, vagina, and oral cavity. <em>C. albicans</em> can become an opportunistic infection when host defenses, physiology, the local microenvironment, or normal resident flora are altered.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>T-lymphocyte-mediated immunity is the primary defense mechanism against candidal infection in humans. Key elements of this mechanism are phagocytosis and killing of yeast organisms by macrophages and neutrophils as well as neutrophil degranulation. Additionally in the skin, dendritic cells phagocytose and kill <em>Candida</em> cells and traffic to local lymph nodes to induce a T cell response [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/1,8,10,11\" class=\"abstract_t\">1,8,10,11</a>]. Secretory and circulating antibodies probably contribute to host defenses. However, the humoral immune system probably plays only a minor role in protecting from yeast infection.</p><p>Patients with T-lymphocyte defects, (eg, HIV infection), with neutropenia, or with altered neutrophil function have increased susceptibility to cutaneous infection with <em>Candida</em>.</p><p>Mechanical maintenance of skin integrity and epidermal proliferation and turnover serve essential protective functions. Local factors such as trauma, occlusion, and maceration, which damage host tissue, can enhance <em>Candida</em> colonization and adhesion. Normal cutaneous bacterial flora provide additional host protection by competing for nutrients, occupying epithelial adhesion sites, and producing metabolic byproducts that are toxic to yeast organisms. A failure in the host defense system including disruption of the skin's integrity by maceration and abrasion, impaired cellular immunity, or alteration of normal skin flora facilitates cutaneous infection by <em>Candida</em> species [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/1,8,12\" class=\"abstract_t\">1,8,12</a>].</p><p><em>Candida</em> species possess a wide range of potential virulence factors that are differentially expressed depending on the site of infection, environmental conditions, and host immune response [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/13\" class=\"abstract_t\">13</a>]. Research has established cell morphology, thigmotropism, adhesion factors, phenotypic switching, and the selective expression of 10 SAP genes that encode extracellular secreted aspartic proteinases (SAP) as key elements of <em>C. albicans</em> pathogenicity [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/11-16\" class=\"abstract_t\">11-16</a>].</p><p>Adhesion to and colonization of the epidermis results from expression of candidal surface glycoproteins including agglutinin-like sequence adhesions that bind collagen, laminin, and extracellular matrix glycoproteins. Glycoproteins on the surface of the yeast can also interact with epidermal membrane glycoproteins in a lectin-like manner to establish adherence [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/11,12\" class=\"abstract_t\">11,12</a>]. In response to environmental stimuli at the site of infection, <em>Candida</em> undergoes a phenotypic change from budding yeast to hyphal and germ tube forms with resultant filamentous or mycelial growth [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/15,17\" class=\"abstract_t\">15,17</a>]. Production of the various SAP, which possess proteolytic activity against keratin, collagen, laminin, fibronectin, and immunoglobulins including secretory IgA, then allows hyphal invasion of the corneal layer.</p><p>Subsequent deeper invasion into the skin occurs by passive endocytosis, proteolytic degradation of host tissue, and by thigmotropism, a mechanism of contact sensing utilized by <em>Candida</em> species [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/11-14\" class=\"abstract_t\">11-14</a>]. Active penetration into the epidermis by hyphae is enhanced by phospholipases localized to the hyphal tips that are responsible for direct injury to host cell membranes and adhesion molecules, thus compromising epidermal integrity [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/11,18,19\" class=\"abstract_t\">11,18,19</a>].</p><p>With invasion, epidermal proliferation and phagocytosis of hyphae by keratinocytes occur [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/12\" class=\"abstract_t\">12</a>]. An inflammatory response is triggered and maintained, in part because pattern recognition receptors on the host cell recognize and interact with pathogen-associated molecular patterns on the fungal cell wall (namely, mannan and beta-glucan), and thus stimulate lymphocyte proliferation, activate complement via the alternative pathway, and induce neutrophil chemotaxis. These proteins also trigger keratinocytes to produce antimicrobial peptides and proinflammatory cytokines and chemokines through activation of toll-like receptors [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/1,11,12,20-23\" class=\"abstract_t\">1,11,12,20-23</a>]. (See <a href=\"topic.htm?path=toll-like-receptors-roles-in-disease-and-therapy\" class=\"medical medical_review\">&quot;Toll-like receptors: Roles in disease and therapy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">CLINICAL FEATURES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Candidal intertrigo exhibits erythematous, macerated plaques and erosions with fine peripheral scaling and erythematous satellite papules and pustules. The pustules are easily ruptured, leaving an erythematous base with a surrounding collarette of epidermis. The plaques are often pruritic and occasionally are painful if significant skin breakdown accompanies the infection (<a href=\"image.htm?imageKey=PC%2F80146\" class=\"graphic graphic_picture graphicRef80146 \">picture 2</a>) [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/1,2,4,24\" class=\"abstract_t\">1,2,4,24</a>].</p><p>Typical locations for candidal intertrigo include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Inguinal folds (<a href=\"image.htm?imageKey=DERM%2F72073\" class=\"graphic graphic_picture graphicRef72073 \">picture 1A</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Axillae (<a href=\"image.htm?imageKey=PC%2F78179\" class=\"graphic graphic_picture graphicRef78179 \">picture 1B</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Scrotum</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intergluteal folds</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Inframammary folds (<a href=\"image.htm?imageKey=DERM%2F71145\" class=\"graphic graphic_picture graphicRef71145 \">picture 1C</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Web spaces of the toes and fingers (<a href=\"image.htm?imageKey=PC%2F79187\" class=\"graphic graphic_picture graphicRef79187 \">picture 1D</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Abdominal folds, particularly beneath a pannus</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Redundant skin at the corners of the mouth in older individuals (perl&egrave;che)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Neck folds in infants (<a href=\"image.htm?imageKey=PEDS%2F62523\" class=\"graphic graphic_picture graphicRef62523 \">picture 1E</a>)</p><p/><p>Examples of unique forms of candidal intertrigo include diaper dermatitis and erosio interdigitalis blastomycetica.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Candidal diaper dermatitis </strong>&ndash; Candidal diaper dermatitis occurs in 4 to 6 percent of term infants with a peak incidence at three to four months of age, but can occur at any age in infants, children, or adults with incontinence. The dermatitis results from cutaneous colonization by yeast from the patient's gastrointestinal tract [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/5\" class=\"abstract_t\">5</a>]. Chronic occlusion by wet diapers predisposes to infection, which initially begins in the perianal area with subsequent extension to the perineum and inguinal creases. The dermatitis appears as erythematous macerated plaques with satellite pustules typical of intertrigo (<a href=\"image.htm?imageKey=PEDS%2F59361%7EPEDS%2F72165\" class=\"graphic graphic_picture graphicRef59361 graphicRef72165 \">picture 3A-B</a>). Persistent candidal diaper dermatitis in young children may be a sign of type 1 diabetes mellitus. (See <a href=\"topic.htm?path=diaper-dermatitis\" class=\"medical medical_review\">&quot;Diaper dermatitis&quot;</a> and <a href=\"topic.htm?path=epidemiology-presentation-and-diagnosis-of-type-1-diabetes-mellitus-in-children-and-adolescents\" class=\"medical medical_review\">&quot;Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Erosio interdigitalis blastomycetica </strong>&ndash; Erosio interdigitalis blastomycetica (EIB), or interdigital candidiasis of the hands and feet, specifically involving the third and fourth interspaces, exhibits erythema and maceration with peripheral desquamation of the web space (<a href=\"image.htm?imageKey=PC%2F79187\" class=\"graphic graphic_picture graphicRef79187 \">picture 1D</a>) [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/1,25\" class=\"abstract_t\">1,25</a>]. EIB most often occurs on the hands due to occupational exposure to moisture or sugar and commonly occurs in bakers, confectioners, fruit handlers, bartenders, housekeepers, and any person wearing gloves for prolonged periods of time [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/2,25\" class=\"abstract_t\">2,25</a>]. Toe web intertrigo is a risk factor for the development of lower extremity cellulitis [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/26\" class=\"abstract_t\">26</a>].</p><p/><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Candidal intertrigo is primarily a clinical diagnosis, based on the typical appearance and distribution of the dermatitis. The presence of satellite papules or pustules is a key finding that supports the diagnosis. The diagnosis can be confirmed by potassium hydroxide (KOH) examination (<a href=\"image.htm?imageKey=PC%2F79879\" class=\"graphic graphic_picture graphicRef79879 \">picture 4</a>) or culture of skin scrapings (<a href=\"image.htm?imageKey=PC%2F50344\" class=\"graphic graphic_picture graphicRef50344 \">picture 5</a>). (See <a href=\"topic.htm?path=office-based-dermatologic-diagnostic-procedures#H4044416\" class=\"medical medical_review\">&quot;Office-based dermatologic diagnostic procedures&quot;, section on 'Potassium hydroxide preparation'</a>.)</p><p>Direct microscopic examination of skin scrapings reveals oval budding yeasts with septate hyphae and pseudohyphae (elongated, filamentous cells connected end to end) (<a href=\"image.htm?imageKey=PC%2F79879\" class=\"graphic graphic_picture graphicRef79879 \">picture 4</a>) [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/1,4,24\" class=\"abstract_t\">1,4,24</a>]. Growth on either bacterial media or Sabouraud's dextrose agar treated with antibiotics yields whitish mucoid colonies after two to five days incubation at room temperature (<a href=\"image.htm?imageKey=PC%2F50344\" class=\"graphic graphic_picture graphicRef50344 \">picture 5</a>) [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/1\" class=\"abstract_t\">1</a>].</p><p>Biopsy is rarely necessary, but it can confirm the diagnosis, revealing parakeratotic scale with underlying subcorneal pustules. The epidermis is spongiotic with neutrophil exocytosis, and prominent edema and a perivascular and interstitial infiltrate of neutrophils are present within the dermis. Periodic acid-Schiff (PAS) or methenamine silver stains allow visualization of the yeast organisms within the stratum corneum [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/18,27\" class=\"abstract_t\">18,27</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Common or important conditions that may mimic intertrigo include [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/1,24\" class=\"abstract_t\">1,24</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Tinea cruris </strong>(<a href=\"image.htm?imageKey=DERM%2F71067\" class=\"graphic graphic_picture graphicRef71067 \">picture 6</a>) (see <a href=\"topic.htm?path=dermatophyte-tinea-infections\" class=\"medical medical_review\">&quot;Dermatophyte (tinea) infections&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Atopic dermatitis</strong> (<a href=\"image.htm?imageKey=PC%2F65407%7EDERM%2F68746\" class=\"graphic graphic_picture graphicRef65407 graphicRef68746 \">picture 7A-B</a>) (see <a href=\"topic.htm?path=atopic-dermatitis-eczema-pathogenesis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Contact dermatitis</strong> (<a href=\"image.htm?imageKey=OBGYN%2F80139\" class=\"graphic graphic_picture graphicRef80139 \">picture 8</a>) (see <a href=\"topic.htm?path=overview-of-dermatitis-eczema#H11\" class=\"medical medical_review\">&quot;Overview of dermatitis (eczema)&quot;, section on 'Contact dermatitis'</a>) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Seborrheic dermatitis</strong> (<a href=\"image.htm?imageKey=DERM%2F53407%7EDERM%2F73813%7EDERM%2F52803\" class=\"graphic graphic_picture graphicRef53407 graphicRef73813 graphicRef52803 \">picture 9A-C</a>) (see <a href=\"topic.htm?path=overview-of-dermatitis-eczema#H2\" class=\"medical medical_review\">&quot;Overview of dermatitis (eczema)&quot;, section on 'Seborrheic dermatitis'</a> and <a href=\"topic.htm?path=seborrheic-dermatitis-in-adolescents-and-adults#H43690682\" class=\"medical medical_review\">&quot;Seborrheic dermatitis in adolescents and adults&quot;, section on 'Seborrheic dermatitis of the trunk and intertriginous areas'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Inverse psoriasis</strong> (<a href=\"image.htm?imageKey=DERM%2F78531\" class=\"graphic graphic_picture graphicRef78531 \">picture 10</a>) (see <a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-psoriasis#H28373595\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, and diagnosis of psoriasis&quot;, section on 'Inverse psoriasis'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Erythrasma</strong> (<a href=\"image.htm?imageKey=DERM%2F51713\" class=\"graphic graphic_picture graphicRef51713 \">picture 11</a>) (see <a href=\"topic.htm?path=erythrasma\" class=\"medical medical_review\">&quot;Erythrasma&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Bacterial intertrigo</strong> secondary to <em>Staphylococcus aureus</em> or group A <em>Streptococcus</em> (<a href=\"image.htm?imageKey=DERM%2F96561\" class=\"graphic graphic_picture graphicRef96561 \">picture 12</a>) (see <a href=\"topic.htm?path=cellulitis-and-skin-abscess-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Cellulitis and skin abscess: Clinical manifestations and diagnosis&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Herpes simplex</strong> (<a href=\"image.htm?imageKey=OBGYN%2F61107\" class=\"graphic graphic_picture graphicRef61107 \">picture 13</a>) (see <a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-infection\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Mycosis fungoides</strong> (<a href=\"image.htm?imageKey=DERM%2F100634\" class=\"graphic graphic_picture graphicRef100634 \">picture 14</a>) (see <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-mycosis-fungoides\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Extramammary Paget disease</strong> (<a href=\"image.htm?imageKey=ONC%2F95067%7EDERM%2F96562\" class=\"graphic graphic_picture graphicRef95067 graphicRef96562 \">picture 15A-B</a>) (see <a href=\"topic.htm?path=vulvar-cancer-epidemiology-diagnosis-histopathology-and-treatment-of-rare-histologies#H12\" class=\"medical medical_review\">&quot;Vulvar cancer: Epidemiology, diagnosis, histopathology, and treatment of rare histologies&quot;, section on 'Paget disease of the vulva'</a>) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Familial benign pemphigus (Hailey-Hailey disease)</strong> (<a href=\"image.htm?imageKey=OBGYN%2F80862\" class=\"graphic graphic_picture graphicRef80862 \">picture 16</a>) (see <a href=\"topic.htm?path=hailey-hailey-disease-benign-familial-pemphigus\" class=\"medical medical_review\">&quot;Hailey-Hailey disease (benign familial pemphigus)&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Glucagonoma syndrome</strong> (<a href=\"image.htm?imageKey=DERM%2F56367\" class=\"graphic graphic_picture graphicRef56367 \">picture 17</a>) (see <a href=\"topic.htm?path=glucagonoma-and-the-glucagonoma-syndrome\" class=\"medical medical_review\">&quot;Glucagonoma and the glucagonoma syndrome&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Langerhans cell histiocytosis</strong>, which should be considered in children who appear to have recalcitrant diaper area dermatitis (<a href=\"image.htm?imageKey=DERM%2F57722%7EDERM%2F69504\" class=\"graphic graphic_picture graphicRef57722 graphicRef69504 \">picture 18A-B</a>) (see <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-langerhans-cell-histiocytosis\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is relatively little evidence regarding the best therapy for candidal intertrigo. The following basic treatment approach to candidal intertrigo is generally successful [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/6,24\" class=\"abstract_t\">6,24</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treat active candidal infection with topical antifungal medication</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>After antifungal treatment, initiate skin care with drying agents to reduce risk of recurrence</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Address other predisposing factors to reduce risk of recurrence</p><p/><p>Treatment with systemic antifungal medication occasionally is necessary for severe cases. (See <a href=\"#H493252\" class=\"local\">'Severe and refractory disease'</a> below.)</p><p class=\"headingAnchor\" id=\"H22110634\"><span class=\"h2\">Treatment of active candidal infection</span></p><p class=\"headingAnchor\" id=\"H491833\"><span class=\"h3\">First-line therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment with a topical antifungal medication is an effective and well-tolerated approach for most patients.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h4\">Topical antifungal agents</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A wide variety of topical antifungal creams, lotions, gels, or ointments have activity against <em>Candida </em>species and can effectively treat candidal intertrigo. Few data exist comparing the treatment of candidal intertrigo with different topical agents, leaving uncertainty about the in vivo relative efficacies of these therapies.</p><p>The main classes of topical agents employed in the treatment of intertrigo are the polyene and azole families. The most commonly used topical antifungal medications are <a href=\"topic.htm?path=nystatin-drug-information\" class=\"drug drug_general\">nystatin</a> (polyene), <a href=\"topic.htm?path=miconazole-drug-information\" class=\"drug drug_general\">miconazole</a>, <a href=\"topic.htm?path=clotrimazole-drug-information\" class=\"drug drug_general\">clotrimazole</a>, <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a>, <a href=\"topic.htm?path=econazole-drug-information\" class=\"drug drug_general\">econazole</a>, and <a href=\"topic.htm?path=sertaconazole-drug-information\" class=\"drug drug_general\">sertaconazole</a> (azoles) (<a href=\"image.htm?imageKey=PC%2F76148\" class=\"graphic graphic_table graphicRef76148 \">table 1</a>). The choice among these agents is based upon cost and availability. <a href=\"topic.htm?path=oxiconazole-drug-information\" class=\"drug drug_general\">Oxiconazole</a>, <a href=\"topic.htm?path=sulconazole-drug-information\" class=\"drug drug_general\">sulconazole</a>, and <a href=\"topic.htm?path=luliconazole-drug-information\" class=\"drug drug_general\">luliconazole</a> [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/28\" class=\"abstract_t\">28</a>] also have activity against <em>Candida</em> species, but their activity is weaker than that of other azoles. </p><p>Other types of antifungal therapies include <a href=\"topic.htm?path=terbinafine-drug-information\" class=\"drug drug_general\">terbinafine</a> and <a href=\"topic.htm?path=naftifine-drug-information\" class=\"drug drug_general\">naftifine</a> (allylamines), <a href=\"topic.htm?path=butenafine-drug-information\" class=\"drug drug_general\">butenafine</a> (a benzylamine), and <a href=\"topic.htm?path=ciclopirox-drug-information\" class=\"drug drug_general\">ciclopirox</a> (a hydroxypyridone) (<a href=\"image.htm?imageKey=PC%2F76148\" class=\"graphic graphic_table graphicRef76148 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/29-34\" class=\"abstract_t\">29-34</a>]. Most topical antifungal agents have some antiinflammatory properties, and ciclopirox has strong activity against both gram-positive and gram-negative bacteria, which often coexist with <em>Candida</em> in intertriginous zones [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/24,29,35\" class=\"abstract_t\">24,29,35</a>].</p><p>Topical antifungal agents should be applied twice daily to the affected area until resolution. Resolution of active infection typically occurs within two weeks. Erythema can remain after candidal infection is successfully treated. A typical treatment course is two to four weeks.</p><p>The topical agents are generally well tolerated and adverse events are uncommon, primarily consisting of burning, irritation, pruritus, erythema, or allergic contact dermatitis at the site of application [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/29\" class=\"abstract_t\">29</a>]. </p><p class=\"headingAnchor\" id=\"H22110715\"><span class=\"h3\">Adjunctive therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Low-potency topical corticosteroids (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 2</a>) may be used in conjunction with antifungal therapy to treat associated pruritus, pain, and burning [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/1\" class=\"abstract_t\">1</a>]. Moderate- and high-potency corticosteroid preparations should be avoided, including products that contain both an antifungal drug and a medium- or high-potency topical corticosteroid (eg, <a href=\"topic.htm?path=clotrimazole-drug-information\" class=\"drug drug_general\">clotrimazole</a> and <a href=\"topic.htm?path=betamethasone-drug-information\" class=\"drug drug_general\">betamethasone</a> dipropionate). Cutaneous atrophy is an adverse effect of long-term corticosteroid use that is most likely to occur with potent corticosteroids used in intertriginous areas. (See <a href=\"topic.htm?path=general-principles-of-dermatologic-therapy-and-topical-corticosteroid-use#H16\" class=\"medical medical_review\">&quot;General principles of dermatologic therapy and topical corticosteroid use&quot;, section on 'Side effects'</a>.)</p><p>Topical combination preparations containing 1% <a href=\"topic.htm?path=iodoquinol-drug-information\" class=\"drug drug_general\">iodoquinol</a> with 2% <a href=\"topic.htm?path=hydrocortisone-drug-information\" class=\"drug drug_general\">hydrocortisone</a> acetate may be safely applied in intertriginous zones for a few weeks and may be an effective alternative for candidal intertrigo based upon in vitro study data demonstrating antimicrobial properties [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/36\" class=\"abstract_t\">36</a>].</p><p>If maceration or weeping is present, compresses with a drying solution, such as Domeboro's, should be applied for 10 to 15 minutes two to three times daily, followed by application of an antifungal cream. </p><p class=\"headingAnchor\" id=\"H493252\"><span class=\"h3\">Severe and refractory disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Systemic antifungal medications are rarely necessary for the treatment of intertrigo. However, in patients with severe or recalcitrant infection, systemic therapy may be beneficial, with a response rate of 80 to 100 percent [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/24,37-39\" class=\"abstract_t\">24,37-39</a>].</p><p class=\"headingAnchor\" id=\"H493575\"><span class=\"h4\">Oral antifungal agents</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment with an oral agent is warranted when a patient has failed topical therapy or has a particularly severe or extensive presentation, eg, multiple intertriginous areas, significant maceration and skin breakdown, or numerous pustules and exudate.</p><p>Systemic therapies for adults with candidal intertrigo include [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/24,37,40-43\" class=\"abstract_t\">24,37,40-43</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">Fluconazole</a> 50 to 100 mg daily or 150 mg weekly</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">Itraconazole</a> 200 mg twice daily</p><p/><p>For children [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/44\" class=\"abstract_t\">44</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">Fluconazole</a> 6 <span class=\"nowrap\">mg/kg</span> once, then 3 <span class=\"nowrap\">mg/kg</span> per day </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">Itraconazole</a> 5 to 10 <span class=\"nowrap\">mg/kg</span> per day divided in two doses </p><p/><p>Therapy is typically two to six weeks or until signs and symptoms have resolved. If resolution does not occur within this period, treatment should be discontinued and the diagnosis should be reevaluated. </p><p>While oral <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> is effective for candidal intertrigo, the risks of oral ketoconazole treatment outweigh the benefits, and it should <strong>not</strong> be used as therapy for cutaneous infections. In July 2013, the European Medicines Agency (EMA) recommended that marketing authorizations for oral ketoconazole be suspended throughout the European Union because of concern regarding the risk for oral ketoconazole-induced severe liver injury [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/45\" class=\"abstract_t\">45</a>]. In addition, the US Food and Drug Administration (FDA) withdrew its indication for the use of oral ketoconazole for <em>Candida</em> and dermatophyte infections because of concerns regarding the drug's safety [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/46\" class=\"abstract_t\">46</a>]. In 2016, following an FDA safety review that found continued prescribing of oral ketoconazole for fungal infections of the skin and nails, the FDA released a drug safety communication again warning health care professionals to <strong>avoid</strong> prescribing oral ketoconazole for cutaneous fungal infections [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/47\" class=\"abstract_t\">47</a>]. (See <a href=\"topic.htm?path=pharmacology-of-azoles#H13\" class=\"medical medical_review\">&quot;Pharmacology of azoles&quot;, section on 'Drug-specific adverse effects'</a> and <a href=\"topic.htm?path=pharmacology-of-azoles#H20\" class=\"medical medical_review\">&quot;Pharmacology of azoles&quot;, section on 'Dosing'</a>.)</p><p>Common adverse effects from <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> and <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> oral antifungal drugs include diarrhea, dyspepsia, nausea, abdominal pain, headache, and morbilliform rash [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/40\" class=\"abstract_t\">40</a>]. Asymptomatic, mild elevations in transaminases may occur in approximately 3 to 4 percent of patients [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/48\" class=\"abstract_t\">48</a>]. Clinically significant hepatotoxicity has been described with these agents, but is a rare event. (See <a href=\"topic.htm?path=pharmacology-of-azoles#H11\" class=\"medical medical_review\">&quot;Pharmacology of azoles&quot;, section on 'Adverse effects'</a>.)</p><p>Drug interactions are a frequent concern with oral antifungal agents, many of which affect the cytochrome P450 mixed function oxidase enzymes. Prescribers must be wary of potential drug-drug interactions whenever prescribing these medications [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/40\" class=\"abstract_t\">40</a>]. (See <a href=\"topic.htm?path=pharmacology-of-azoles#H31\" class=\"medical medical_review\">&quot;Pharmacology of azoles&quot;, section on 'Drug interactions'</a>.)</p><p class=\"headingAnchor\" id=\"H493333\"><span class=\"h2\">Preventive measures</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Preventive measures help to reduce factors that promote candidal infection and skin irritation. For example, drying agents to reduce moisture and maceration, interventions to reduce medical risk factors, and intermittent use of topical antifungal agents may reduce susceptibility to intertrigo. Patients should avoid occlusive clothing and promote aeration of susceptible areas.</p><p>In general, long-term suppressive therapy with systemic antifungals is discouraged due to the potential for clinical tolerance, microbial resistance, and subsequent colonization with the more resistant <em>Candida</em> species [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/9\" class=\"abstract_t\">9</a>].</p><p class=\"headingAnchor\" id=\"H22111203\"><span class=\"h3\">Skin care</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Use of topical drying agents after treatment of active infection is important in the prevention of intertrigo, since they reduce moisture and maceration. Patients at risk for recurrence should use a drying agent indefinitely.</p><p>Commonly used drying agents include antifungal powders (eg, <a href=\"topic.htm?path=miconazole-drug-information\" class=\"drug drug_general\">miconazole</a>, <a href=\"topic.htm?path=nystatin-drug-information\" class=\"drug drug_general\">nystatin</a>, <a href=\"topic.htm?path=undecylenic-acid-and-derivatives-drug-information\" class=\"drug drug_general\">undecylenic acid</a>, and <a href=\"topic.htm?path=tolnaftate-drug-information\" class=\"drug drug_general\">tolnaftate</a>). Other agents are aluminum sulfate <a href=\"topic.htm?path=calcium-acetate-drug-information\" class=\"drug drug_general\">calcium acetate</a> solution (Domeboro's solution), <a href=\"topic.htm?path=gentian-violet-drug-information\" class=\"drug drug_general\">gentian violet</a> solution, carbol-fuchsin solution (Castellani's paint), and antiseptic drying agents such as potassium permanganate solution [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/6,24,49\" class=\"abstract_t\">6,24,49</a>].</p><p>Talcum powder has been used as a drying agent [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/6,24,50\" class=\"abstract_t\">6,24,50</a>]; however, there is controversy over whether use of talc in the genital area of women increases risk for ovarian cancer [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/51\" class=\"abstract_t\">51</a>]. Corn starch is an inexpensive alternative that effectively may protect against frictional injury without enhancing the growth of yeast [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/50\" class=\"abstract_t\">50</a>]. (See <a href=\"topic.htm?path=epithelial-carcinoma-of-the-ovary-fallopian-tube-and-peritoneum-epidemiology-and-risk-factors#H6092263\" class=\"medical medical_review\">&quot;Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors&quot;, section on 'Talc and asbestos'</a>.)</p><p class=\"headingAnchor\" id=\"H493131\"><span class=\"h3\">Improvement of predisposing medical conditions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of predisposing factors is an important component of successful treatment. Obesity, incontinence, and underlying conditions, such as diabetes mellitus may contribute to infection [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/4\" class=\"abstract_t\">4</a>].</p><p>If obesity is present, weight loss should be encouraged [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/3\" class=\"abstract_t\">3</a>]. Women with chronic intertrigo under pendulous breasts have benefited from reduction mammoplasty [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/52\" class=\"abstract_t\">52</a>]; however, such surgery is rarely primary treatment for intertrigo.</p><p>Skin maceration and irritation from chronic incontinence in older adult patients can contribute to intertrigo in the groin area. A structured skin care routine and the use of efficacious absorbent hygiene products (eg, adult diapers, incontinence briefs, underwear liners) can ameliorate skin breakdown and reduce the risk of <em>Candida</em> infection [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/53-55\" class=\"abstract_t\">53-55</a>].</p><p class=\"headingAnchor\" id=\"H22112855\"><span class=\"h3\">Intermittent antifungal therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Intermittent (eg, twice-weekly) use of topical antifungal is sometimes used in an attempt to decrease the likelihood of recurrent candidal infection. Although reasonable, such treatment has not been confirmed in clinical studies. </p><p>There are data to support the use of <a href=\"topic.htm?path=chlorhexidine-gluconate-drug-information\" class=\"drug drug_general\">chlorhexidine</a> rinses in the prevention of oral candidiasis [<a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/56\" class=\"abstract_t\">56</a>]; however, the efficacy of prophylactic chlorhexidine washes in the prevention of candidal intertrigo has not been evaluated.</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intertrigo is any infectious or noninfectious inflammatory condition of two closely opposed skin surfaces (intertriginous area). While intertrigo may result from the overgrowth of microorganisms including bacteria, candidal intertrigo specifically refers to superficial infection with <em>Candida</em> species (candidal intertrigo). (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The risk of candidal intertrigo is increased by factors that increase skin friction and moisture, decrease the immune response, or promote fungal overgrowth. Examples include occlusive or chafing clothing, obesity, diabetes, and infection with human immunodeficiency virus (HIV). (See <a href=\"#H2\" class=\"local\">'Etiology and risk factors'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Typical locations for candidal intertrigo include the groin, axillae, inframammary and abdominal folds, and the web spaces of fingers and toes (<a href=\"image.htm?imageKey=DERM%2F72073%7EPC%2F78179%7EDERM%2F71145%7EPC%2F79187%7EPEDS%2F62523\" class=\"graphic graphic_picture graphicRef72073 graphicRef78179 graphicRef71145 graphicRef79187 graphicRef62523 \">picture 1A-E</a>). Candidal intertrigo exhibits erythematous, macerated plaques and erosions with peripheral scaling and erythematous satellite papules and pustules. The dermatitis is frequently pruritic. (See <a href=\"#H5\" class=\"local\">'Clinical features'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Candidal intertrigo can often be diagnosed based upon its typical appearance. The diagnosis can be confirmed by potassium hydroxide (KOH) examination and culture of skin scrapings. (See <a href=\"#H6\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment should include amelioration of predisposing factors (eg, avoidance of occlusive clothing) and underlying conditions (eg, weight reduction, treatment of diabetes). (See <a href=\"#H493131\" class=\"local\">'Improvement of predisposing medical conditions'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most patients can be successfully treated with a topical antifungal agent (cream, lotion, ointment, or gel). We suggest choosing a topical antifungal agent based on availability, cost, and clinician familiarity with the agent (<a href=\"image.htm?imageKey=PC%2F76148\" class=\"graphic graphic_table graphicRef76148 \">table 1</a>). (See <a href=\"#H11\" class=\"local\">'Topical antifungal agents'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>After treatment, patients should use a drying agent to help maintain a dry environment on the skin and minimize maceration and reinfection. In particular, patients prone to recurrent candidal intertrigo should use a drying agent on a daily basis. (See <a href=\"#H493333\" class=\"local\">'Preventive measures'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest treating severe or recalcitrant disease with oral <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> or oral <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a>. (See <a href=\"#H493252\" class=\"local\">'Severe and refractory disease'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li class=\"breakAll\">Klenk AS, Martin AG, Heffernan MP. Yeast infections: candidiasis, pityriasis (tinea) versicolor. In: Dermatology in General Medicine, Freedberg IM, Eisen AZ, Wolff K, et al (Eds), McGraw-Hill, New York 2003. p.2006.</li><li class=\"breakAll\">Yaar M, Gilchrest BA. Aging of skin. In: Fitzpatrick's Dermatology in General Medicine, Freedberg IM, Eisen AZ, Wolff K, et al (Eds), McGraw-Hill, New York 2003. p.1386.</li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/3\" class=\"nounderline abstract_t\">Garc&iacute;a Hidalgo L. Dermatological complications of obesity. Am J Clin Dermatol 2002; 3:497.</a></li><li class=\"breakAll\">Sobera JO, Elewski BE. Fungal Diseases. In: Dermatology, Bolognia JL, Jorizzo JL, Rapini RP (Eds), Mosby, London 2003. p.1171.</li><li class=\"breakAll\">Friedlander SF, Rueda M, Chen BK, Caceres-Rios HW. Fungal, protozoal, and helminthic infections. In: Pediatric Dermatology, Schachner LA, Hansen RC (Eds), Mosby, Edinburgh 2003. p.1093.</li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/6\" class=\"nounderline abstract_t\">Hay RJ. The management of superficial candidiasis. J Am Acad Dermatol 1999; 40:S35.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/7\" class=\"nounderline abstract_t\">Jautov&aacute; J, Baloghov&aacute; J, Dorko E, et al. Cutaneous candidosis in immunosuppressed patients. Folia Microbiol (Praha) 2001; 46:359.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/8\" class=\"nounderline abstract_t\">Hay RJ. Yeast infections. Dermatol Clin 1996; 14:113.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/9\" class=\"nounderline abstract_t\">Hay RJ. Antifungal therapy of yeast infections. J Am Acad Dermatol 1994; 31:S6.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/10\" class=\"nounderline abstract_t\">Mansour MK, Levitz SM. Interactions of fungi with phagocytes. Curr Opin Microbiol 2002; 5:359.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/11\" class=\"nounderline abstract_t\">H&ouml;fs S, Mogavero S, Hube B. Interaction of Candida albicans with host cells: virulence factors, host defense, escape strategies, and the microbiota. J Microbiol 2016; 54:149.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/12\" class=\"nounderline abstract_t\">Odds FC. Pathogenesis of Candida infections. J Am Acad Dermatol 1994; 31:S2.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/13\" class=\"nounderline abstract_t\">Hube B, Naglik J. Candida albicans proteinases: resolving the mystery of a gene family. Microbiology 2001; 147:1997.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/14\" class=\"nounderline abstract_t\">Schaller M, Schackert C, Korting HC, et al. Invasion of Candida albicans correlates with expression of secreted aspartic proteinases during experimental infection of human epidermis. J Invest Dermatol 2000; 114:712.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/15\" class=\"nounderline abstract_t\">Calderone RA. Host-parasite relationships in candidosis. Mycoses 1989; 32 Suppl 2:12.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/16\" class=\"nounderline abstract_t\">Costa CR, Jesu&iacute;no RS, de Aquino Lemos J, et al. Effects of antifungal agents in sap activity of Candida albicans isolates. Mycopathologia 2010; 169:91.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/17\" class=\"nounderline abstract_t\">Bahn YS, Sundstrom P. CAP1, an adenylate cyclase-associated protein gene, regulates bud-hypha transitions, filamentous growth, and cyclic AMP levels and is required for virulence of Candida albicans. J Bacteriol 2001; 183:3211.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/18\" class=\"nounderline abstract_t\">Scherwitz C. Ultrastructure of human cutaneous candidosis. J Invest Dermatol 1982; 78:200.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/19\" class=\"nounderline abstract_t\">Mukherjee PK, Seshan KR, Leidich SD, et al. Reintroduction of the PLB1 gene into Candida albicans restores virulence in vivo. Microbiology 2001; 147:2585.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/20\" class=\"nounderline abstract_t\">Cassone A, Marconi P, Bistoni F. Cell wall of Candida albicans and host response. Crit Rev Microbiol 1987; 15:87.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/21\" class=\"nounderline abstract_t\">Beaus&eacute;jour A, Grenier D, Goulet JP, Deslauriers N. Proteolytic activation of the interleukin-1beta precursor by Candida albicans. Infect Immun 1998; 66:676.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/22\" class=\"nounderline abstract_t\">Schaller M, Mailhammer R, Korting HC. Cytokine expression induced by Candida albicans in a model of cutaneous candidosis based on reconstituted human epidermis. J Med Microbiol 2002; 51:672.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/23\" class=\"nounderline abstract_t\">Li M, Chen Q, Shen Y, Liu W. Candida albicans phospholipomannan triggers inflammatory responses of human keratinocytes through Toll-like receptor 2. Exp Dermatol 2009; 18:603.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/24\" class=\"nounderline abstract_t\">Guitart J, Woodley DT. Intertrigo: a practical approach. Compr Ther 1994; 20:402.</a></li><li class=\"breakAll\">Friedmann PS, Wilkinson M. Occupational dermatoses. In: Dermatology, Bolognia JL, Jorizzo JL, Rapini RP (Eds), Mosby, London 2003. p.251.</li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/26\" class=\"nounderline abstract_t\">Dupuy A, Benchikhi H, Roujeau JC, et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ 1999; 318:1591.</a></li><li class=\"breakAll\">Kauffman CL, Hamet VH, Tahan SR. Fungal infections. In: Textbook of Dermatopathology, Barnhill RL (Ed), McGraw-Hill, New York 2004. p.479.</li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/28\" class=\"nounderline abstract_t\">Koga H, Nanjoh Y, Makimura K, Tsuboi R. In vitro antifungal activities of luliconazole, a new topical imidazole. Med Mycol 2009; 47:640.</a></li><li class=\"breakAll\">Phillips RM, Rosen T. Topical antifungal agents. In: Comprehensive Dermatologic Drug Therapy, 3rd ed, Wolverton SE (Ed), W.B. Saunders, Philadelphia 2001. p.497.</li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/30\" class=\"nounderline abstract_t\">McClellan KJ, Wiseman LR, Markham A. Terbinafine. An update of its use in superficial mycoses. Drugs 1999; 58:179.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/31\" class=\"nounderline abstract_t\">Villars V, Jones TC. Clinical efficacy and tolerability of terbinafine (Lamisil)--a new topical and systemic fungicidal drug for treatment of dermatomycoses. Clin Exp Dermatol 1989; 14:124.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/32\" class=\"nounderline abstract_t\">Croxtall JD, Plosker GL. Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology. Drugs 2009; 69:339.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/33\" class=\"nounderline abstract_t\">Gupta AK, Ryder JE, Cooper EA. Naftifine: a review. J Cutan Med Surg 2008; 12:51.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/34\" class=\"nounderline abstract_t\">Gupta AK, Plott T. Ciclopirox: a broad-spectrum antifungal with antibacterial and anti-inflammatory properties. Int J Dermatol 2004; 43 Suppl 1:3.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/35\" class=\"nounderline abstract_t\">Gupta AK, Bluhm R. Ciclopirox shampoo for treating seborrheic dermatitis. Skin Therapy Lett 2004; 9:4.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/36\" class=\"nounderline abstract_t\">Burnett BP, Mitchell CM. Antimicrobial activity of iodoquinol 1%-hydrocortisone acetate 2% gel against ciclopirox and clotrimazole. Cutis 2008; 82:273.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/37\" class=\"nounderline abstract_t\">Stengel F, Robles-Soto M, Galimberti R, Suchil P. Fluconazole versus ketoconazole in the treatment of dermatophytoses and cutaneous candidiasis. Int J Dermatol 1994; 33:726.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/38\" class=\"nounderline abstract_t\">Nozickova M, Koudelkova V, Kulikova Z, et al. A comparison of the efficacy of oral fluconazole, 150 mg/week versus 50 mg/day, in the treatment of tinea corporis, tinea cruris, tinea pedis, and cutaneous candidosis. Int J Dermatol 1998; 37:703.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/39\" class=\"nounderline abstract_t\">Coldiron BM, Manders SM. Persistent Candida intertrigo treated with fluconazole. Arch Dermatol 1991; 127:165.</a></li><li class=\"breakAll\">Gupta AK. Systemic antifungal agents. In: Comprehensive Dermatologic Drug Therapy, Wolverton SE (Ed), W.B. Saunders, Philadelphia 2001. p.55.</li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/41\" class=\"nounderline abstract_t\">Pi&eacute;rard GE, Arrese JE, De Doncker P. Antifungal activity of itraconazole and terbinafine in human stratum corneum: a comparative study. J Am Acad Dermatol 1995; 32:429.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/42\" class=\"nounderline abstract_t\">Daning L, Dinguo Z, Wenwei S, Peihong J. Extensive skin candidosis in an adult: effective treatment with itraconazole. Mycoses 1998; 41:219.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/43\" class=\"nounderline abstract_t\">Del Rosso JQ, Zellis S, Gupta AK. Itraconazole in the treatment of superficial cutaneous and mucosal Candida infections. J Am Osteopath Assoc 1998; 98:497.</a></li><li class=\"breakAll\">American Academy of Pediatrics. Antimicrobial agents and related therapy. In: Red Book: 2009 Report of the Committee on Infectious Diseases, 28th, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009. p.737.</li><li class=\"breakAll\">www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/07/news_detail_001855.jsp&amp;mid=WC0b01ac058004d5c1 (Accessed on July 26, 2013).</li><li class=\"breakAll\">www.fda.gov/Drugs/DrugSafety/ucm362415.htm (Accessed on July 26, 2013).</li><li class=\"breakAll\">www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm502073.htm (Accessed on May 23, 2016).</li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/48\" class=\"nounderline abstract_t\">Katz HI, Gupta AK. Oral antifungal drug interactions: a mechanistic approach to understanding their cause. Dermatol Clin 2003; 21:543.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/49\" class=\"nounderline abstract_t\">Sundaram SV, Srinivas CR, Thirumurthy M. Candidal intertrigo: treatment with filter paper soaked in Castellani's paint. Indian J Dermatol Venereol Leprol 2006; 72:386.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/50\" class=\"nounderline abstract_t\">Leyden JJ. Corn starch, Candida albicans, and diaper rash. Pediatr Dermatol 1984; 1:322.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/51\" class=\"nounderline abstract_t\">Cramer DW, Liberman RF, Titus-Ernstoff L, et al. Genital talc exposure and risk of ovarian cancer. Int J Cancer 1999; 81:351.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/52\" class=\"nounderline abstract_t\">Chadbourne EB, Zhang S, Gordon MJ, et al. Clinical outcomes in reduction mammaplasty: a systematic review and meta-analysis of published studies. Mayo Clin Proc 2001; 76:503.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/53\" class=\"nounderline abstract_t\">Runeman B. Skin interaction with absorbent hygiene products. Clin Dermatol 2008; 26:45.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/54\" class=\"nounderline abstract_t\">Gray M. Optimal management of incontinence-associated dermatitis in the elderly. Am J Clin Dermatol 2010; 11:201.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/55\" class=\"nounderline abstract_t\">Farage MA, Miller KW, Berardesca E, Maibach HI. Incontinence in the aged: contact dermatitis and other cutaneous consequences. Contact Dermatitis 2007; 57:211.</a></li><li><a href=\"https://www.uptodate.com/contents/candidal-intertrigo/abstract/56\" class=\"nounderline abstract_t\">Barasch A, Safford MM, Dapkute-Marcus I, Fine DH. Efficacy of chlorhexidine gluconate rinse for treatment and prevention of oral candidiasis in HIV-infected children: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 97:204.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 4026 Version 17.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H16\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">ETIOLOGY AND RISK FACTORS</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">MICROBIOLOGY</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">PATHOGENESIS</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">CLINICAL FEATURES</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">DIAGNOSIS</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">MANAGEMENT</a><ul><li><a href=\"#H22110634\" id=\"outline-link-H22110634\">Treatment of active candidal infection</a><ul><li><a href=\"#H491833\" id=\"outline-link-H491833\">- First-line therapy</a><ul><li><a href=\"#H11\" id=\"outline-link-H11\">Topical antifungal agents</a></li></ul></li><li><a href=\"#H22110715\" id=\"outline-link-H22110715\">- Adjunctive therapy</a></li><li><a href=\"#H493252\" id=\"outline-link-H493252\">- Severe and refractory disease</a><ul><li><a href=\"#H493575\" id=\"outline-link-H493575\">Oral antifungal agents</a></li></ul></li></ul></li><li><a href=\"#H493333\" id=\"outline-link-H493333\">Preventive measures</a><ul><li><a href=\"#H22111203\" id=\"outline-link-H22111203\">- Skin care</a></li><li><a href=\"#H493131\" id=\"outline-link-H493131\">- Improvement of predisposing medical conditions</a></li><li><a href=\"#H22112855\" id=\"outline-link-H22112855\">- Intermittent antifungal therapy</a></li></ul></li></ul></li><li><a href=\"#H16\" id=\"outline-link-H16\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/4026|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/72073\" class=\"graphic graphic_picture\">- Candidal intertrigo groin</a></li><li><a href=\"image.htm?imageKey=PC/78179\" class=\"graphic graphic_picture\">- Severe axillary intertrigo</a></li><li><a href=\"image.htm?imageKey=DERM/71145\" class=\"graphic graphic_picture\">- Inframammary Candida intertrigo</a></li><li><a href=\"image.htm?imageKey=PC/79187\" class=\"graphic graphic_picture\">- Finger web intertrigo</a></li><li><a href=\"image.htm?imageKey=PEDS/62523\" class=\"graphic graphic_picture\">- Candidal intertrigo neck folds</a></li><li><a href=\"image.htm?imageKey=PC/80146\" class=\"graphic graphic_picture\">- Abdominal and inguinal intertrigo</a></li><li><a href=\"image.htm?imageKey=PEDS/59361\" class=\"graphic graphic_picture\">- Candidal diaper dermatitis A</a></li><li><a href=\"image.htm?imageKey=PEDS/72165\" class=\"graphic graphic_picture\">- Candidal diaper dermatitis B</a></li><li><a href=\"image.htm?imageKey=PC/79879\" class=\"graphic graphic_picture\">- Pseudohyphae candida albicans</a></li><li><a href=\"image.htm?imageKey=PC/50344\" class=\"graphic graphic_picture\">- Candida albicans culture plate</a></li><li><a href=\"image.htm?imageKey=DERM/71067\" class=\"graphic graphic_picture\">- Tinea cruris 3</a></li><li><a href=\"image.htm?imageKey=PC/65407\" class=\"graphic graphic_picture\">- Severe atopic dermatitis</a></li><li><a href=\"image.htm?imageKey=DERM/68746\" class=\"graphic graphic_picture\">- Atopic dermatitis infant</a></li><li><a href=\"image.htm?imageKey=OBGYN/80139\" class=\"graphic graphic_picture\">- Contact derm vulva2</a></li><li><a href=\"image.htm?imageKey=DERM/53407\" class=\"graphic graphic_picture\">- Seborrheic dermatitis axilla</a></li><li><a href=\"image.htm?imageKey=DERM/73813\" class=\"graphic graphic_picture\">- Seborrheic dermatitis diaper area</a></li><li><a href=\"image.htm?imageKey=DERM/52803\" class=\"graphic graphic_picture\">- Infantile seborrheic dermatitis multiple sites</a></li><li><a href=\"image.htm?imageKey=DERM/78531\" class=\"graphic graphic_picture\">- Inverse psoriasis chest</a></li><li><a href=\"image.htm?imageKey=DERM/51713\" class=\"graphic graphic_picture\">- Intertriginous erythrasma</a></li><li><a href=\"image.htm?imageKey=DERM/96561\" class=\"graphic graphic_picture\">- Perianal streptococcal infection</a></li><li><a href=\"image.htm?imageKey=OBGYN/61107\" class=\"graphic graphic_picture\">- HSV primary</a></li><li><a href=\"image.htm?imageKey=DERM/100634\" class=\"graphic graphic_picture\">- Mycosis fungoides in axilla</a></li><li><a href=\"image.htm?imageKey=ONC/95067\" class=\"graphic graphic_picture\">- Scrotal extramammary Paget disease</a></li><li><a href=\"image.htm?imageKey=DERM/96562\" class=\"graphic graphic_picture\">- Extramammary Paget disease</a></li><li><a href=\"image.htm?imageKey=OBGYN/80862\" class=\"graphic graphic_picture\">- Hailey Hailey</a></li><li><a href=\"image.htm?imageKey=DERM/56367\" class=\"graphic graphic_picture\">- Necrolytic migratory erythema perineum</a></li><li><a href=\"image.htm?imageKey=DERM/57722\" class=\"graphic graphic_picture\">- Langerhans histiocytosis skin 1</a></li><li><a href=\"image.htm?imageKey=DERM/69504\" class=\"graphic graphic_picture\">- Langerhans histiocytosis skin 2</a></li></ul></li><li><div id=\"DERM/4026|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PC/76148\" class=\"graphic graphic_table\">- Topical antifungal agents</a></li><li><a href=\"image.htm?imageKey=DERM/62402\" class=\"graphic graphic_table\">- Topical corticosteroids</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=atopic-dermatitis-eczema-pathogenesis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cellulitis-and-skin-abscess-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Cellulitis and skin abscess: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-langerhans-cell-histiocytosis\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-mycosis-fungoides\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=dermatophyte-tinea-infections\" class=\"medical medical_review\">Dermatophyte (tinea) infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diaper-dermatitis\" class=\"medical medical_review\">Diaper dermatitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-infection\" class=\"medical medical_review\">Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-psoriasis\" class=\"medical medical_review\">Epidemiology, clinical manifestations, and diagnosis of psoriasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-presentation-and-diagnosis-of-type-1-diabetes-mellitus-in-children-and-adolescents\" class=\"medical medical_review\">Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epithelial-carcinoma-of-the-ovary-fallopian-tube-and-peritoneum-epidemiology-and-risk-factors\" class=\"medical medical_review\">Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=erythrasma\" class=\"medical medical_review\">Erythrasma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=general-principles-of-dermatologic-therapy-and-topical-corticosteroid-use\" class=\"medical medical_review\">General principles of dermatologic therapy and topical corticosteroid use</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=glucagonoma-and-the-glucagonoma-syndrome\" class=\"medical medical_review\">Glucagonoma and the glucagonoma syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hailey-hailey-disease-benign-familial-pemphigus\" class=\"medical medical_review\">Hailey-Hailey disease (benign familial pemphigus)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=office-based-dermatologic-diagnostic-procedures\" class=\"medical medical_review\">Office-based dermatologic diagnostic procedures</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-dermatitis-eczema\" class=\"medical medical_review\">Overview of dermatitis (eczema)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacology-of-azoles\" class=\"medical medical_review\">Pharmacology of azoles</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=seborrheic-dermatitis-in-adolescents-and-adults\" class=\"medical medical_review\">Seborrheic dermatitis in adolescents and adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=toll-like-receptors-roles-in-disease-and-therapy\" class=\"medical medical_review\">Toll-like receptors: Roles in disease and therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vulvar-cancer-epidemiology-diagnosis-histopathology-and-treatment-of-rare-histologies\" class=\"medical medical_review\">Vulvar cancer: Epidemiology, diagnosis, histopathology, and treatment of rare histologies</a></li></ul></div></div>","javascript":null}